Quantcast
Home > Quotes > AEMD

Aethlon Medical, Inc. Common Stock (AEMD) Quote & Summary Data

AEMD 
$1.2663
*  
0.0037
0.29%
Get AEMD Alerts
*Delayed - data as of Dec. 12, 2018 10:07 ET  -  Find a broker to begin trading AEMD now
Exchange:NASDAQ
Industry: Capital Goods
Community Rating:
View:    AEMD Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 1.26 / $ 1.29
1 Year Target
4.875
Today's High / Low
$ 1.27 / $ 1.239
Share Volume
12,346
50 Day Avg. Daily Volume
350,350
Previous Close
$ 1.27
52 Week High / Low
$ 2.04 / $ 0.8216
Market Cap
22,611,740
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.89

Intraday Chart

Shares Traded

Share Volume:
12,346
50 Day Avg. Daily Volume:
350,350

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.28

Trading Range

The current last sale of $1.2663 is 54.13% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.27 $ 2.04
 Low: $ 1.239 $ 0.8216

Company Description (as filed with the SEC)

We are a therapeutic technology company focused on addressing unmet needs in global health and biodefense. In the field of infectious disease therapeutics, a majority of viruses that transmit human infections are not addressed with approved antiviral therapies. To address this significant unmet need, the Aethlon Hemopurifier┬« is an affinity hemofiltration device developed for the single-use elimination of life-threatening viruses from the human circulatory system. In the United States, we are advancing the Hemopurifier under a "Breakthrough Device" designation from The United States Food and Drug Administration (FDA). Under the "Breakthrough Device" program, the FDA has permitted the proposed "Indication for Use" for our device to include: "The Hemopurifier is a single-use device indicated for the treatment of life-threatening glycosylated viruses that are not addressed with an approved therapy.  ... More ...  


Risk Grade

Where does AEMD fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.27
Open Date:
Dec. 12, 2018
Close Price:
$ 1.27
Close Date:
Dec. 11, 2018

Consensus Recommendation

Analyst Info